Rehovot, Israel

Vishnu Mohan

This inventor holds 1 USPTO granted patent. Top assignee: Yeda Research and Develpment & Co. Ltd. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vishnu Mohan. Retrieved from https://idiyas.com/inventor/vishnu-mohan-2fwoz1zb

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Vishnu Mohan: Innovator in MMP-7 Inhibition

Introduction

Vishnu Mohan is a notable inventor based in Rehovot, Israel. He has made significant contributions to the field of biomedical research, particularly in the development of therapeutic antibodies.

Latest Patents

Vishnu Mohan holds a patent for an "Anti-matrix metalloproteinase 7 (MMP-7) inhibitory antibody and uses thereof." This patent describes a method for treating diseases associated with imbalanced or abnormal activity of MMP-7. The method involves the administration of an antibody that binds to the catalytic site of MMP-7, utilizing specific amino acid sequences in its structure.

Career Highlights

Mohan's career is marked by his work at Yeda Research and Development Co. Ltd., where he has been involved in pioneering research. His innovative approach has led to advancements in therapeutic strategies targeting MMP-7.

Collaborations

Mohan collaborates with Irit Sagi, a fellow researcher, to further explore the implications of MMP-7 inhibition in various diseases.

Conclusion

Vishnu Mohan's work exemplifies the intersection of innovation and medical research, showcasing the potential of targeted therapies in treating complex diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…